BX471 hydrochloride
| CAS No. | 288262-96-4 | Cat. No. | BCP32594 |
| Name | BX471 hydrochloride | ||
| Synonyms | ZK-811752 hydrochloride;BX471 HCl;ZK 811752 HCl; | ||
| Formula | C21H25Cl2FN4O3 | M. Wt | 471.35 |
| Description | BX-471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX-471 exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX-471 was developed Berlex and its parent company, Schering AG. BX-471 is the lead in a series of non-peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In March 2000, BX-471 was undergoing phase I trials for the potential treatment of autoimmune diseases. | ||
| Pathways | GPCR/G Protein | ||
| Targets | CXCR CCR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.